Gene · 8744
Papers3,166
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
361 to 380 of 3,166
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A new marker constructed from immune-related lncRNA pairs can be used to predict clinical treatment effects and prognosis: in-depth exploration of underlying mechanisms in HNSCC. | World J Surg Oncol | 2023 | 37592311 | PubTator, text mining | PubMed |
| Hepatocellular carcinoma cell differentiation trajectory predicts immunotherapy, potential therapeutic drugs, and prognosis of patients. | Open Life Sci | 2023 | 37589009 | PubTator, text mining | PubMed |
| Sleeping Beauty kit sets provide rapid and accessible generation of artificial antigen-presenting cells for natural killer cell expansion. | Immunol Cell Biol | 2023 | 37585342 | PubTator, text mining | PubMed |
| Identification of lysosomal genes associated with prognosis in lung adenocarcinoma. | Transl Lung Cancer Res | 2023 | 37577321 | PubTator, text mining | PubMed |
| Characterization and Prognosis of Biological Microenvironment in Lung Adenocarcinoma through a Disulfidptosis-Related lncRNAs Signature. | Genet Res (Camb) | 2023 | 37575978 | PubTator, text mining | PubMed |
| FcγR requirements and costimulatory capacity of Urelumab, Utomilumab, and Varlilumab. | Front Immunol | 2023 | 37575254 | PubTator, text mining | PubMed |
| Adenovirus-assembled DC vaccine induces dual-targeting CTLs for tumor antigen and adenovirus to eradicate tumors. | Int Immunopharmacol | 2023 | 37573687 | PubTator, text mining | PubMed |
| Navigating the Blood-Brain Barrier: Challenges and Therapeutic Strategies in Breast Cancer Brain Metastases. | Int J Mol Sci | 2023 | 37569410 | PubTator, text mining | PubMed |
| Identification of a Novel Eight-Gene Risk Model for Predicting Survival in Glioblastoma: A Comprehensive Bioinformatic Analysis. | Cancers (Basel) | 2023 | 37568715 | PubTator, text mining | PubMed |
| Chimeric antigen receptor engineered natural killer cells for cancer therapy. | Exp Hematol Oncol | 2023 | 37563648 | PubTator, text mining | PubMed |
| Prognostic and immune infiltrative biomarkers of CENPO in pan-cancer and its relationship with lung adenocarcinoma cell proliferation and metastasis. | BMC Cancer | 2023 | 37558987 | PubTator, text mining | PubMed |
| Identification and validation of a novel HOX-related classifier signature for predicting prognosis and immune microenvironment in pediatric gliomas. | Front Cell Dev Biol | 2023 | 37547473 | PubTator, text mining | PubMed |
| Identification and validation of a genetic risk signature associated with prognosis in clear-cell renal cell carcinoma patients. | Medicine (Baltimore) | 2023 | 37543772 | PubTator, text mining | PubMed |
| Disulfidptosis-associated LncRNAs index predicts prognosis and chemotherapy drugs sensitivity in cervical cancer. | Sci Rep | 2023 | 37528124 | PubTator, text mining | PubMed |
| Axicabtagene Ciloleucel in Combination with the 4-1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11. | Clin Cancer Res | 2023 | 37527011 | PubTator, text mining | PubMed |
| Optimized conditions for gene transduction into primary immune cells using viral vectors. | Sci Rep | 2023 | 37524755 | PubTator, text mining | PubMed |
| Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality. | J Transl Med | 2023 | 37518011 | PubTator, text mining | PubMed |
| 2B4 inhibits the apoptosis of natural killer cells through phosphorylated extracellular signal-related kinase/B-cell lymphoma 2 signal pathway. | Cytotherapy | 2023 | 37516949 | PubTator, text mining | PubMed |
| Systemic inflammatory proteins in offspring following maternal probiotic supplementation for atopic dermatitis prevention. | Clin Mol Allergy | 2023 | 37516841 | PubTator, text mining | PubMed |
| Bridging Pyroptosis and Immunity: A Comprehensive Study of the Pyroptosis-Related Long Non-Coding RNA Signature in Breast Cancer. | Life (Basel) | 2023 | 37511974 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8744/papers?page=19